Multiomic profiling of human and canine soft-tissue sarcomas reveals extensive molecular homology across species and identifies clinically relevant subgroups

This study presents a comprehensive multiomic analysis of human and canine soft-tissue sarcomas, revealing extensive molecular homology between species, redefining fibrosarcoma and myxofibrosarcoma as a molecular continuum with clinically relevant subgroups, and validating the dog as a valuable translational model for developing targeted therapies.

The Gist

Imagine you are trying to solve a mystery where two different groups of criminals (tumors) look almost identical on the outside, but you need to know their inner secrets to catch them. This is the story of Soft-Tissue Sarcomas (STS), a rare and tricky type of cancer that affects both humans and dogs.

For a long time, doctors have struggled to tell these tumors apart or find the right medicine to stop them. This paper is like a high-tech detective story where scientists used a "molecular microscope" to compare human and canine tumors side-by-side, discovering that dogs and humans are actually fighting the same biological battle.

Here is the breakdown of their findings using simple analogies:

1. The "Twin Cities" Analogy: Humans and Dogs

Think of human cancer patients and pet dogs as two different cities. Usually, when scientists study a disease, they look at one city and guess how it works in the other. But this study realized that Human City and Dog City are built on the exact same blueprint.

• The Discovery: The researchers found that the "fibrosarcoma" (FSA) and "myxofibrosarcoma" (MFS) tumors in dogs are molecularly almost identical to those in humans.
• Why it matters: Dogs get these tumors much more often than humans. By studying dogs, scientists can learn about the disease faster, essentially using dogs as a "living laboratory" to test new cures that could save both species.

2. The "Continuum" vs. The "Wall"

Traditionally, doctors thought FSA and MFS were two completely different species of tumors, separated by a high wall.

• The New View: The study found that there is no wall. Instead, these tumors exist on a sliding scale (a continuum).
• The Analogy: Imagine a color gradient. On one end, you have a tumor that is very "immune-active" (the body's security guards are fighting hard). On the other end, you have a tumor that is "proliferative" (the cancer cells are just multiplying like crazy).
• The Result: A tumor labeled "FSA" in one patient might be biologically more similar to an "MFS" in another patient than it is to other "FSA" tumors. The old labels based on how they look under a microscope are misleading; we need to label them by their molecular behavior.

3. The "Secret Club" in Dogs

While most dog and human tumors were on that sliding scale, the scientists found a secret club of 15 dog tumors that didn't fit anywhere.

• The Mystery: These tumors looked like regular fibrosarcomas but had a unique genetic "fingerprint."
• The Smoking Gun: They all shared a specific genetic glitch called a gene fusion (imagine two different instruction manuals glued together incorrectly). This created a new type of cancer driven by a specific protein switch (MNT-NCOA2).
• The Impact: This means some dogs diagnosed with "regular" cancer actually have a distinct, new subtype that might need a completely different treatment.

4. The "Good Cop vs. Bad Cop" Strategy

The study looked at what was happening inside the tumors to predict who would survive longer.

• The Good Cop (Immune Activation): In some tumors, the body's immune system (the security guards) was actively trying to fight the cancer. Patients with these "busy" tumors tended to live longer.
• The Bad Cop (Cell Cycle): In other tumors, the immune system was asleep, but the cancer cells were in overdrive, multiplying rapidly. These patients had a harder time.
• The Lesson: The key to survival isn't just how big the tumor is, but how the immune system is reacting to it. This suggests that treatments designed to wake up the immune system (immunotherapy) could be a game-changer.

5. Finding the "Achilles Heel"

Finally, the researchers looked for "tumor-exclusive" targets—parts of the cancer cell that are not found in healthy tissue.

• The Analogy: Imagine trying to find a specific key that only opens the cancer's front door, without touching the healthy house next door.
• The Findings: They found several "keys" (proteins like HSPA5, TK1, and TTK) that were present in almost all the tumors but absent in healthy muscle or fat.
• The Future: These proteins are perfect targets for new drugs or even special dyes that would light up the tumor during surgery, helping surgeons remove every last bit of cancer while leaving healthy tissue alone.

The Big Picture

This paper is a bridge. It proves that dogs are not just pets; they are partners in medical research. Because their tumors behave so similarly to ours, and because they develop naturally (not in a lab cage), studying them gives us a massive head start.

By realizing that human and canine sarcomas are molecular twins, and by identifying specific subtypes and "Achilles heels," this research paves the way for precision medicine—tailoring treatments to the specific genetic makeup of the tumor, offering hope for better outcomes for both humans and their four-legged friends.

Technical Summary

1. Problem Statement

Soft-tissue sarcomas (STS) are a heterogeneous group of rare mesenchymal tumors with over 100 recognized human subtypes. Despite advances in cytogenetics, diagnostic precision remains low for many subtypes, and therapeutic options are limited.

• Diagnostic Challenges: Human Fibrosarcoma (FSA) is a diagnosis of exclusion with few molecular markers, while Myxofibrosarcoma (MFS) is common but poorly understood mechanistically.
• Translational Gap: Canine STS occurs spontaneously with high incidence and morphological similarity to human STS, making dogs valuable translational models. However, routine veterinary diagnosis relies on coarse histomorphology, lacking the molecular resolution required for direct cross-species comparison.
• Data Deficit: There is a lack of tissue-resolved, multiomic data (transcriptomic and proteomic) comparing tumor tissue against matched adjacent normal tissue (NT) in both species. Bulk tissue analyses often obscure tumor-specific signals due to stromal contamination.

2. Methodology

The study employed a rigorous, tissue-resolved multiomic approach using archival Formalin-Fixed Paraffin-Embedded (FFPE) specimens.

• Cohort Selection:
  • Human: 23 FSA (including infantile, adult, and sclerosing epithelioid variants) and 27 MFS cases.
  • Canine: 30 FSA and 31 MFS cases.
  • Controls: Matched adjacent normal tissues (Adipose, Connective, Skeletal Muscle) were collected where available.
• Sample Preparation:
  • Laser-Capture Microdissection (LCM): Used to isolate pure tumor and specific normal tissue regions from FFPE sections, ensuring high purity and eliminating stromal contamination.
  • Multiomic Profiling:
    • Transcriptomics: RNA sequencing (RNAseq) using SMARTer Stranded Total RNAseq kits.
    • Proteomics: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) using data-independent acquisition (DIA) on an Orbitrap Fusion Lumos.
• Bioinformatic Analysis:
  • Data Processing: Alignment to human (GRCh38) and canine (CanFam3.1) genomes; ortholog mapping for cross-species comparison.
  • Statistical Methods: Differential expression analysis (DESeq2/edgeR/limma), Principal Component Analysis (PCA), unsupervised hierarchical clustering, Gene Set Enrichment Analysis (GSEA), and Single Sample GSEA (ssGSEA).
  • Genomic Alterations: Detection of gene fusions (STAR-Fusion), somatic mutations, and Copy Number Alterations (CNA) via SuperFreq and GISTIC.
  • Cross-Species Validation: Used SingleR for cell-type annotation, AGDEX (Agreement of Differential Expression) for cross-species correlation, and regulon analysis (RTN) for transcriptional networks.

3. Key Contributions

• First Comprehensive Cross-Species Multiomic Atlas: Established the first tissue-resolved transcriptomic and proteomic comparison of human and canine FSA and MFS.
• Redefining STS Subtypes: Demonstrated that FSA and MFS likely represent a molecular continuum rather than distinct entities in both species, challenging current histological classifications.
• Discovery of a Novel Canine Subtype: Identified a distinct canine STS subcluster driven by a specific MNT-NCOA2 gene fusion, suggesting a new diagnostic entity.
• Identification of Clinically Relevant Subgroups: Defined molecular subgroups based on immune activation and proliferative activity that correlate with patient survival, independent of histological grade.
• Therapeutic Target Discovery: Identified tumor-exclusive proteins and genes conserved across species, offering candidates for targeted therapy and intraoperative imaging.

4. Key Results

A. Molecular Continuum and Subgrouping

• Human Data: PCA and clustering revealed that human FSA and MFS overlap significantly. However, human FSA split into two distinct clusters:
  • hFSA C1: High immune infiltration, associated with a trend toward longer disease-free survival (DFS).
  • hFSA C2: High proliferative activity (G2M/E2F signatures), low immune infiltration, high expression of immune checkpoints (CTLA4, PD-L1), and poorer DFS.
• Canine Data: Similar to humans, canine FSA and MFS formed a continuous molecular spectrum. However, a distinct cSubcluster (15 tumors) emerged, characterized by:
  • Low immune/inflammatory response.
  • High epithelial-to-mesenchymal transition (EMT) and angiogenesis signatures.
  • Presence of a novel MNT-NCOA2 gene fusion in 7/15 cases. This fusion creates a chimeric protein activating MYC targets, suggesting a distinct oncogenic driver.

B. Genomic Alterations

• Mutations: Low tumor mutational burden (TMB) across all groups (<2.5 Mut/Mb). Recurrent mutations found in NBPF11, AHNAK, and FCGBP.
• Copy Number Alterations (CNA):
  • hFSA C2 showed significant amplifications (e.g., 8q23.1 involving MYC, 12q14.2 involving MDM2) and deletions.
  • hH4 Cluster (immune-high, cell-cycle-low) showed no significant CNAs, correlating with the best clinical outcomes.
• Fusions: ETV6-NTRK3 confirmed in infantile FSA. The novel MNT-NCOA2 fusion in the canine cSubcluster was validated as a driver of MYC activation.

C. Cross-Species Homology

• Conservation: AGDEX and correlation analyses confirmed that canine tumors closely recapitulate human disease at the transcriptomic and proteomic levels.
• Pathways: Both species showed conserved activation of cell cycle, DNA repair, and MYC targets, and conserved downregulation of immune response and muscle development pathways in tumors vs. normal tissue.
• Regulons: Transcriptional network analysis identified common upstream regulators (e.g., MYBL2, FOXM1 activated; IKZF1 deactivated) across species.

D. Therapeutic Targets

• Tumor-Exclusive Targets: The study identified proteins exclusively present in tumors (absent in matched normal tissue) across both species.
  • Top Candidates: HSPA5 (Heat Shock Protein A5) was identified as a tumor-exclusive protein in all subtypes and species. It is involved in the unfolded protein response and promotes therapy resistance.
  • Other Targets: TK1, TTK, FSCN1, PLOD3, and SPARC.
• Diagnostic Potential: These targets offer potential for intraoperative near-infrared (NIR) imaging to guide complete resection and for developing targeted therapeutics.

5. Significance

• Clinical Impact: The study proposes a molecular reclassification of FSA and MFS, moving away from purely histological definitions toward biologically defined subgroups (immune-high vs. proliferative-high) that better predict patient outcomes.
• Translational Model: It validates the dog as a superior preclinical model for human STS due to spontaneous tumor development, intact immune systems, and molecular conservation. This supports the use of canine trials for testing immunotherapies and targeted agents before human application.
• Precision Oncology: The identification of the MNT-NCOA2 fusion in dogs suggests a need for molecular testing in veterinary diagnostics, potentially mirroring future human diagnostic standards.
• Therapeutic Development: The discovery of cross-species, tumor-exclusive targets like HSPA5 provides immediate candidates for drug development and imaging probes, addressing the critical lack of effective treatments for STS.

In summary, this work bridges the gap between veterinary and human oncology, providing a high-resolution molecular map of soft-tissue sarcomas that redefines disease subtypes, uncovers novel drivers, and identifies actionable therapeutic targets.